How SGLT2 inhibitors came to dominate the cardiorenal IP landscape

SGLT2 inhibitors — led by dapagliflozin — are overwhelmingly the dominant therapeutic modality across retrieved patent and literature records for diabetic kidney disease (DKD) and heart failure with preserved ejection fraction (HFpEF), with more than 20 AstraZeneca patent filings spanning 14 jurisdictions between 2020 and 2025. The pharmacological basis is the inhibition of the sodium-glucose cotransporter 2 protein encoded by SLC5A2 in the proximal nephron, which reduces tubular glucose reabsorption and exerts hemodynamic effects — including reduction of intraglomerular pressure, natriuresis, and vascular stiffness — that are mechanistically distinct from the antidiabetic effect.

The clinical foundation underpinning this IP density is substantial. The DAPA-HF Phase 3 trial — cited by name across numerous AstraZeneca patent texts — enrolled patients with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes. Dapagliflozin demonstrated benefit in 55% of patients without T2D, establishing diabetes-independent cardiovascular and heart failure effects that form the basis for patent claims covering both diabetic and non-diabetic populations. The DAPA-CKD Phase 3 trial similarly provides the clinical backbone for CKD-specific filings, with primary and secondary endpoints — eGFR decline ≥40%, end-stage renal disease (ESRD), and cardiovascular death — named directly as patent claim endpoints in filings including the 2021 Israel patent.

Academic literature in the dataset reinforces the mechanistic breadth of SGLT2 inhibition. A meta-analysis from the First Affiliated Hospital of Yangtze University synthesises data from both EMPEROR-Reduced and DAPA-HF, demonstrating benefit across key subgroups including T2D status, age, and baseline eGFR. Separately, research from Lausanne University Hospital identifies kidney hypoxia attenuation as a mechanistic contributor to renoprotection beyond glycemic control — a finding that strengthens the rationale for SGLT2 inhibitor use in non-diabetic CKD. According to WHO, chronic kidney disease affects approximately 10% of the global population, providing a vast addressable patient population for this mechanism class.

The jurisdictional breadth of AstraZeneca’s filings — spanning AU, BR, CA, CN, ID, IL, JP, KR, MX, PE, SG, TW, US, and WO — reflects a deliberate defensive and broad-coverage IP strategy. Filing the same core disclosure across multiple jurisdictions while progressively adding combination claims creates layered protection that competitors developing SGLT2 inhibitor combinations will need to navigate carefully. Parties entering this space should closely evaluate claim scope in key markets including the US, Japan, Australia, China, and EU via designated states, as advised by WIPO‘s patent landscape reporting methodology.

From steroidal MRAs to non-steroidal modulators: the AZD9977 strategy

The mineralocorticoid receptor (MR/NR3C2) axis represents the second major target cluster in the cardiorenal pipeline, and the transition from classical steroidal MRAs to non-steroidal modulators is the most strategically significant shift visible in the retrieved IP data. AstraZeneca’s AZD9977 — a non-steroidal selective MR modulator — is the most prominently disclosed compound in this category, appearing across multiple patent filings including a fixed-dose combination (FDC) pharmaceutical composition patent that pairs AZD9977 with dapagliflozin in a pellet-based formulation for CKD or heart failure.

The clinical rationale for this combination is directly articulated in retrieved patent texts: the SGLT2 inhibitor component attenuates the hyperkalemia risk associated with MR blockade, while providing complementary renoprotection through distinct tubular mechanisms. This is supported by translational evidence from a post-hoc analysis of 4,304 dapagliflozin-treated CKD patients, which found that only 229 patients (5.3%) were on steroidal MRA at baseline. The analysis found no significant interaction between MRA use and the cardiorenal benefit of dapagliflozin (P interaction = 0.59), though the upper bound of the confidence interval among MRA-treated patients could reflect up to 47% greater risk — a finding with direct implications for combination trial design.

Real-world outcomes data from the SWEDEHEART registry (2005–2014), published by researchers at Karolinska Institutet, provides complementary context: the analysis describes associations between MRA use and all-cause mortality in myocardial infarction-heart failure patients stratified by left ventricular ejection fraction (LVEF) and CKD status, supporting the clinical relevance of MRA therapy across the cardiorenal continuum. The aldosterone synthase inhibition approach — pursued by Boehringer Ingelheim International (Formula I compounds) and Mineralys Therapeutics (lorundrostat) — represents a parallel strategy, preventing aldosterone biosynthesis upstream via CYP11B2 inhibition rather than antagonising the receptor. According to EMA guidance on cardiorenal endpoints, upstream aldosterone blockade may provide more complete suppression of aldosterone-driven fibrosis and inflammation in CKD.

“The SGLT2 inhibitor component in combination with AZD9977 reduces hyperkalemia risk — a clinically important differentiator enabling MR modulator use in lower eGFR patients, particularly those with eGFR 15–59 mL/min/1.73 m².”

Six combination strategies reshaping DKD and HFpEF treatment

The retrieved patent dataset reveals six distinct combination approaches converging on CKD, DKD, and heart failure, each targeting a mechanistically distinct vulnerability in the cardiorenal disease pathway. These represent the forward edge of pipeline activity beyond SGLT2 inhibitor monotherapy.

Endothelin receptor antagonism for high-proteinuria DKD

The convergence of three companies — AstraZeneca (zibotentan + dapagliflozin), Chinook Therapeutics (atrasentan + SGLT2 inhibitor), and Idorsia Pharmaceuticals (aprocitentan + SGLT2 inhibitor) — on ERA plus SGLT2 inhibitor combinations signals a distinct cardiorenal sub-niche for high-proteinuria DKD. The endothelin-1–driven vasoconstriction and glomerular hypertension mechanism is mechanistically complementary to SGLT2-mediated renoprotection, particularly in patients with residual proteinuria despite RAAS blockade. All three ERA + SGLT2i combination filings carry pending legal status, indicating this is an emerging rather than mature development area.

Epigenetic and transporter-based combinations

Resverlogix Corp.’s apabetalone (RVX-208, a BET bromodomain inhibitor) combined with an SGLT2 inhibitor demonstrates a synergistic eGFR improvement signal in patent data: a median eGFR increase from 114 to 120 mL/min at last visit, exceeding the additive effect of monotherapy. This combination targets epigenetic regulation of inflammatory and fibrotic pathways alongside tubular glucose handling, representing a mechanistically differentiated approach. Separately, Jnana Therapeutics’ SLC6A19 inhibitor combination targets two distinct renal tubular transporters — B0AT1 (neutral amino acid transporter) alongside SGLT2 — arguing that dual transporter blockade provides greater CKD protection than either alone. As documented in patent literature reviewed by USPTO, these early-stage filings represent innovation vectors that may become significant clinical candidates.

HFpEF: the significant unmet-need gap in the IP dataset

Heart failure with preserved ejection fraction (HFpEF) — characterised by diastolic dysfunction with preserved left ventricular ejection fraction (LVEF) — receives comparatively limited dedicated IP coverage in the retrieved dataset despite representing a major clinical burden, particularly in patients with DKD who often have preserved LVEF. The only dedicated non-SGLT2 HFpEF-specific modality identified is HDAC6 inhibition by Tenaya Therapeutics, which discloses fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazole HDAC6 inhibitors for HFpEF and metabolic disease.

The HDAC6 target is mechanistically distinct from the RAAS and cardiorenal axis dominant in other retrieved results. HDAC6 deacetylase activity is implicated in cytoskeletal regulation and proteostasis relevant to cardiac diastolic dysfunction — a pathway not addressed by SGLT2 inhibition or MR modulation. Tenaya Therapeutics’ patent text explicitly identifies HFpEF as a condition with unmet need distinct from HFrEF, and evidence is entirely patent-based, placing this at a preclinical to early clinical development stage.

The sacubitril/valsartan literature in the dataset further confirms the gap: a retrospective study of 247 maintenance hemodialysis patients with HFpEF assessed sacubitril/valsartan and noted the absence of effective targeted therapies for HFpEF in this population. AstraZeneca’s pending 2025 Brazil filing for RXFP1 modulator plus SGLT2 inhibitor combinations represents an antifibrotic and vasodilatory approach that may be relevant to HFpEF or cardiorenal fibrosis — relaxin has antifibrotic and vasodilatory properties relevant to heart failure — but this remains an early-stage, pending filing. The combination of limited IP coverage and significant clinical burden positions HFpEF as a high-priority opportunity for developers with novel mechanism-of-action compounds, as noted in cardiac failure research published by NEJM.

Assignee landscape and freedom-to-operate considerations

AstraZeneca AB and its affiliates (AstraZeneca Aktiebolag, AstraZeneca Sweden Co. Ltd.) are, by a substantial margin, the most active assignee in the retrieved dataset, with more than 25 patent filings across at least 14 jurisdictions. Coverage spans dapagliflozin in HFrEF (DAPA-HF data), CKD (DAPA-CKD data), and the novel AZD9977 plus dapagliflozin combination for cardiorenal disease. AstraZeneca’s IP strategy is defensive and broad-coverage: filing the same core disclosure across multiple jurisdictions while progressively adding combination claims — MR modulator, RXFP1, ERA — creates layered protection with significant freedom-to-operate implications for competitors.

Boehringer Ingelheim International GmbH is active across aldosterone synthase inhibitor patents for CKD (Chile and Brazil jurisdictions), SGLT2 inhibitor veterinary applications, and DPP4 inhibitor (linagliptin) plus metformin combinations for CKD metabolic management — demonstrating a multi-cardiometabolic-renal portfolio strategy. Resverlogix Corp. holds a family of patents across WO, AU, MX, NZ, and US jurisdictions for apabetalone plus SGLT2 inhibitor combinations, representing a specialised epigenetic strategy that synergises with SGLT2 inhibition. Smaller assignees — Mineralys Therapeutics, Jnana Therapeutics, Chinook Therapeutics, Idorsia Pharmaceuticals, and Tenaya Therapeutics — each hold one to two filings at pending status, consistent with earlier development stages.

Academic contributors in the dataset include Karolinska Institutet (MRA outcomes in MI-HF via SWEDEHEART registry), Northwestern Medicine (SGLT2 inhibitor clinical pathway in CKD), Brigham and Women’s Hospital/Harvard Medical School (SGLT2 inhibitor initiation in worsening HF), and Yokohama City University (kidney effects of DPP4 inhibitor versus GLP-1 receptor agonist added to SGLT2 inhibitor in T2DM-CKD). This academic-commercial distribution is characteristic of a mature-to-late-stage therapeutic area where commercial IP activity is concentrated, and translational literature provides supporting mechanistic and outcomes evidence. The PatSnap Eureka platform enables systematic monitoring of both patent filings and literature across this space, while PatSnap Analytics provides assignee-level portfolio benchmarking for competitive intelligence.